The present joint European Association of Neuro-Oncology (EANO) – European Society for Medical Oncology (ESMO) recommendations for the diagnosis and treatment of parenchymal brain metastasis (BM) from solid cancers complement the first joint EANO–ESMO guideline on leptomeningeal metastasis from solid cancers [1]. These recommendations address BMs from solid tumours, but do not address BMs from primary brain tumours or BMs from lymphoma or leukaemia. The recommendations cover prevention, diagnosis, therapy and follow-up, but not differential diagnosis, adverse effects of therapeutic measures or supportive or palliative care. Given the low level of evidence, the recommendations are often based on expert opinion and consensus rather than on evidence from informative clinical trials. Still, the EANO–ESMO multidisciplinary recommendations shall serve as a valuable source of information for physicians and other health care providers, as well as informed patients and relatives.

Click here to read published version

Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong YK, Winkler F, Schadendorf D, van den Bent M, Seoane J, Stahel R, Minniti G, Wesseling P, Weller M, Preusser M, on behalf of the EANO Executive Board and ESMO Guidelines Committee, EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours†, Annals of Oncology (2021), doi: https://doi.org/10.1016/j.annonc.2021.07.016.